Rozanolixizumab is a Monoclonal Antibody owned by UCB, and is involved in 15 clinical trials, of which 9 were completed, 5 are ongoing, and 1 is planned.

Rozanolixizumab acts by blocking the neonatal Fc receptor (FcRn)-IgG interaction. FcRn binds to the Fc portion of IgG and protects it from degradation by the lysosome resulting in long serum IgG half-life. The drug candidate binds to the FcRn and inhibits its interaction with IgG regulating the responses of innate and adaptive immune cells.

The revenue for Rozanolixizumab is expected to reach a total of $3.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rozanolixizumab NPV Report.

Rozanolixizumab is originated and owned by UCB.

Rozanolixizumab Overview

Rozanolixizumab (UCB-7665) is under development for the treatment of leucine-rich glioma inactivated 1 autoimmune encephalitis, idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy (CIDP), myelin oligodendrocyte glycoprotein (MOG)-associated disease (demyelinating disorder), fibromyalgia syndrome and myasthenia gravis. It is a new biological entity (NBE). The drug candidate is administered subcutaneously as infusion.

UCB Overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.

Quick View – Rozanolixizumab

Report Segments
  • Innovator
Drug Name
  • Rozanolixizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
  • Immunology
Key Companies
  • Sponsor Company: UCB
  • Originator: UCB
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.